550 Phase I and pharmacokinetic (PK) study of trabectedin (ET-743) administered as a 1-hour infusion weekly for 3 consecutive weeks every 4 weeks to patients with advanced cancer

✍ Scribed by S.Q. Chu; G. Schwartz; M. Beeram; A. Patniak; M. Mita; J. Jimeno; L. Lopez-Larazo; M. Izquerido; L. Flores; E. Rowinsky

• Book ID: 118621732
• Publisher: Elsevier Science
• Year: 2004
• Tongue: English
• Weight: 273 KB
• Volume: 2
• Category: Article
• ISSN: 1359-6349
• DOI: 10.1016/s1359-6349(04)80558-5